Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Open access

Abstract

= .024) and exceeded cell killing by the PI3K-δ-specific inhibitor idelalisib. Administration of duvelisib to mice engrafted with a PTCL patient-derived xenograft resulted in a shift among tumor-associated macrophages from the immunosuppressive M2-like phenotype to the inflammatory M1-like phenotype. In summary, duvelisib demonstrated promising clinical activity and an acceptable safety profile in relapsed/refractory TCL, as well as preclinical evidence of both tumor cell-autonomous and immune-mediated effects. This trial was registered at www.clinicaltrials.gov as #NCT01476657.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2017-08-802470

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 318

Metadata

Authors
Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., Allen, K., Douglas, M., Stern, H., Sweeney, J., Kelly, P., Kelly, V., Aster, J. C., Weaver, D., Foss, F. M., & Weinstock, D. M.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Harvard University (US)
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Broad Institute (US)
  • Infinity Pharmaceuticals (United States) (US)
  • Brigham and Women's Hospital (US)
  • Verastem (United States) (US)
  • Yale Cancer Center (US)
Corresponding author
  • Horwitz, Steven M.
  • Koch, Raphael
  • Foss, Francine M.
  • Weinstock, David M.
Venue
Blood
Published
2018-02-22
Volume
131
Issue
8
Pages
888-898
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2775080684
Cited by
290
References
45
Citations by year
2026: 18 · 2025: 27 · 2024: 32 · 2023: 37 · 2022: 41 · 2021: 45 · 2020: 41 · 2019: 31 · 2018: 18
FWCI
19.33
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR001863)
  • U.S. Food and Drug Administration
  • National Human Genome Research Institute (U54HG008097)
  • National Cancer Institute (P30CA008748)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
duvelisib, T-cell lymphoma, relapsed/refractory lymphoma, PTCL, patient-derived xenografts, tumor-associated macrophages, macrophage polarization, idelalisib
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Isoquinolines, Male, Middle Aged, Prognosis, Purines, Safety, Skin Neoplasms, Tissue Distribution, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Maximum Tolerated Dose, Class I Phosphatidylinositol 3-Kinases, Class Ib Phosphatidylinositol 3-Kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. https://app.cochat.ai/papers/10.1182/blood-2017-08-802470
The paper
Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., Allen, K., Douglas, M., Stern, H., Sweeney, J., Kelly, P., Kelly, V., Aster, J. C., Weaver, D., Foss, F. M., & Weinstock, D. M. (2018). Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. https://doi.org/10.1182/blood-2017-08-802470

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.